Emcure to consider Q4FY26 results, final dividend on May 5

Emcure Pharmaceuticals informed exchanges that its Board will meet on May 5, 2026 to approve Q4FY26 and FY26 audited results and consider final dividend recommendation. Promoter holding remained stable at 77.87%. FIIs held 3.35%, DIIs maintained 6.10%, while public shareholding rose to 12.69%. Shareholder count increased to 1,22,189.